Image

Global Anti-cancer Drug Market - Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Anti-cancer Drug Market, By Indication (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Others), Drug (Cytotoxics, Hormonal Therapy, Targeted Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Industry Trends and Forecast to 2029.

Anti-cancer Drug Market

Global Anti-cancer Drug Market Analysis and Insights

Cancer is a threatening ailment wherein cancer cells multiply to develop a tumor in thepatient's body in a particular organ. These cancerous cells damage the functioning of that particular organ leaving the body vulnerable and weak. Therefore, anti-cancer drugs are the medications that are given to the cancer patients to battle cancerous cells. 

  • The anti-cancer drug treatment is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the anti-cancer drug market will grow at a CAGR of 7.40% during the forecast period of 2022 to 2029. This indicates that the market value was valued at 144.99 billion in 2021 and would stand tall by USD 256.66 billion by 2029.

Anti-cancer Drug Market Dynamics

Drivers

  • Cancer prevalance

Surging incidence rate of different types of cancer such as beast cancer, liver cancer, skin cancer and much more is directly propelling the demand for effective medical treatment. Lung cancer has the highest incidence rate of all which indicates that increase in prevalence rate would directly affect the demand for anti-cancer drugs.        

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the market's growth rate is the rising healthcare expenditure, which helps in improving its infrastructure. Growth and expansion of healthcare industry especially in the developing economies would invite the use and application of new and advanced medial technologies, equipment and drugs. This will directly increase the demand for anti-cancer drugs.

  • Research and development activities

Growing number of strategic collaboration between public and private market players is inducing growth in the number of research and development activities on daily basis. These research and development proficiencies are being conducted in novel drugs and medical technologies that will propel the demand for anti-cancer drugs.

Furthermore, emergence of novel treatment and awareness about cancer, rising initiatives by public and private organizations to spread awareness and increase in popularity of advance therapies are the factors that will expand the market growth rate. Other factors such as increase in the demand for effective therapies, availability of cost effective drugs and rising adoption rate for early diagnostic procedures will positively impact the market's growth rate.

Opportunities

Rise in the level of personal disposable income and growing awareness in the developing economies pertaining to the availability of treatment options will further create lucrative market growth opportunities. Rising medical tourism globally, the higher number of potential drugs in the pipeline, increasing involvement of key players in product development and high potential of growth in the untapped market will create enough market growth opportunities.  

Restraints/Challenges Global Anti-cancer Drug Market

However, high costs associated with research and development proficiencies and high cost involved in new drug development coupled with threat of failure and adverse effects will emerge as one of the biggest restraints for the market. Dearth of awareness and required infrastructural facilities in the underdeveloped and backward economies, stringent government regulations towards approval of biosimilars and unfavourable conditions arising due to COVID-19 outbreak will further derail the market growth rate. Slow rate of approval for drugs and inhibitors, unmet medical needs and increasing cases of patent expiry will also challenge the market growth rate. 

This anti-cancer drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on anti-cancer drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

According to an article published in JAMA Network in August 2020, in United States from March 1, 2020, to April 18, 2020, there was a significant devcline in breast cancer diagnoses, particularly by 51.8%. However, 1 in  women suffer from breast cancer in the U.S. In men, it is 1 in 1000.  

The anti-cancer drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Anti-cancer Drug Market

COVID-19 has given a slight setback to the market. Delay in diagnostic rate is one of the major factors responsible for this setback. Further, supply shortage of drugs and inhibitors in the market has restricted the growth during the pandemic phase. However, it must be noted that the pateints suffering from breast cancer have a higher probability of getting hit with coronavirus.

Recent Development

  • Merck Co. & Inc. received the United States Food & Drug Administration approval in November 2020, for Keytruda in combination with chemotherapy in the treatment of triple-negative breast cancer.

Global Anti-cancer Drug Market Scope

The anti-cancer drug market is segmented on the basis of indication, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

  • Breast Cancer
  • Blood Cancer
  • Prostate Cancer
  • Gastrointestinal Cancer
  • Gynecologic Cancer
  • Lung Cancer
  • Others

On the basis of indication, the global anti-cancer drug market is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, gynecologic cancer, lung cancer and others.

Drug

  • Cytotoxics
  • Hormonal Therapy
  • Targeted Therapy
  • Others

Based on drug, the global anti-cancer drug market is segmented into cytotoxics, hormonal therapy, targeted therapy and others.

Route of administration

  • Oral
  • Parenteral
  • Others

Route of administration segment of global anti-cancer drug market is segmented into oral, parenteral and others.  

End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

On the basis of end-users, the global anti-cancer drug market is segmented into hospitals, homecare, specialty clinics and others.

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

On the basis of distribution channel, the global anti-cancer drug market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy.

Pipeline Analysis

The University of Sussex identified the role of lemur tyrosine kinase 3 (LMTK3) in the cell proliferation in breast cancer in November 2020 and since then are planning to advance the research toward developing LMTK3 specific drugs. Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Eisai Co. Ltd, and Merck & Co. Inc. and others are the involved in the development of potential drugs for the improvement of treatment of breast cancer.

Anti-cancer Drug Market Regional Analysis/Insights

The proctitis market is analysed and market size insights and trends are provided by country, indication, drug class, route of administration, end-users and distribution channel as referenced above.

The countries covered in the proctitis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the proctitis market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players, well-developed healthcare infrastructure in this region and increase in the incidence of proctitis and favorable reimbursement policies.

Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the increase in the awareness about proctitis in developing countries and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Anti-cancer Drug Market Share Analysis

The proctitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to proctitis market.

Some of the major players operating in the proctitis market are Pfizer Inc, AstraZeneca, ANI Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Cipla Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, Fresenius Kabi AG, Mayne Pharma Group Limited, Mylan N.V., Novartis AG., Vintage Labs, Dr. Reddy's Laboratories Ltd, Jiangsu Hengrui Medicine Co., Ltd, Novo Nordisk A/S, Otsuka America Pharmaceutical, Inc., and WOCKHARDT others.

Research Methodology : Global Anti-cancer Drug Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-anti-cancer-drug-market


SKU-
Why Choose Us


Frequently Asked Questions

The Anti-cancer Drug Market will be projected to grow at a CAGR of 7.40% during the forecast by 2029.
The Anti-cancer Drug Market will be projected at USD 256.66 billion during the forecast by 2029.
The major players operating in the Anti-cancer Drug Market are Pfizer Inc, AstraZeneca, ANI Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Cipla Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, Fresenius Kabi AG, Mayne Pharma Group Limited, Mylan N.V., Novartis AG., Vintage Labs, Dr. Reddy's Laboratories Ltd, Jiangsu Hengrui Medicine Co., Ltd, Novo Nordisk A/S, Otsuka America Pharmaceutical, Inc., and WOCKHARDT others.
The significant factors flourishing the growth of the Anti-cancer Drug Market are Cancer prevalance, Increasing investment for healthcare infrastructure and Research and development activities.